- TheStreet.com•6 hours ago
Adamis Pharmaceuticals (ADMP) could benefit from rival Mylan's (MYL) high price of EpiPens as its own product is reportedly close to approval.
- Barrons.com•10 hours ago
Adamis Pharmaceuticals (ADMP:Nasdaq) By Maxim Group ($2.99, Aug. 24, 2016) We believe Adamis Pharmaceuticals’ pre-filled syringe is close to becoming an approved product. Mylan’s (MYL) EpiPen was mentioned in the press as an example of “price gouging,” highlighting the significant price increase of the product. Adamis’ (ADMP) pre-filled syringe (PFS) could be the solution.
The pharmaceutical company announced that it will increase its patient assistance program in hopes of quelling a growing backlash over its drug pricing.
Adamis Pharmaceuticals Corporation (ADMP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||3.73 x 100|
|Ask||3.73 x 200|
|Day's Range||2.83 - 3.57|
|52wk Range||2.50 - 10.98|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.55|
|Avg Vol (3m)||422,315|
|Dividend & Yield||N/A (N/A)|